Comparing the current results to its competitors, Bio Path Holdings Inc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 2.32 %, recorded in the same quarter.
Bio path Holdings inc , slower than the average decrease reported by the company's competitors of -96.66 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -96.66 %
Bio Path Holdings Inc 's Comment on Competition and Industry Peers
The company focuses on protecting its platform and target-specific technology to deter competitors and create value. It plans to pursue a proactive licensing program that may include co-development, sub-licensing, or out-licensing of liposomal antisense drug candidates. Research and development expenses primarily cover third-party clinical, preclinical, and manufacturing activities, as well as salaries, benefits, and stock-based compensation related to advancing its drug candidate pipeline.
May 1, 2025
In a notable development for the biopharmaceutical sector, Bio-Path Holdings, Inc. (NASDAQ: BPTH) has announced it has achieved its third pre-clinical milestone in its efforts to advance BP1001-A, a promising treatment aimed at tackling obesity, particularly in patients with Type 2 diabetes. This innovative program signifies a pivotal shift in the company’s focus, as it marks the first non-cancer application of Bio-Path s proprietary DNAbilize technology, specifically designed for targeted nucleic acid delivery.The importance of this milestone cannot be understated. BP1001-A has demonstrated compelling pre-clinical data suggesting its ability to prevent fatty acid-induced insulin resistance in cellular mod...
December 19, 2024
Bio-Path Holdings Advances BP1001-A: A New Prospect for Treating Obesity in Type 2 Diabetes Patients Bio-Path Holdings Inc has announced the commencement of preclinical testing for its new therapeutic candidate, BP1001-A, which may offer a promising solution in enhancing insulin sensitivity for individuals suffering from obesity and type 2 diabetes. The recent preclinical studies have not only confirmed the mechanism of action of BP1001-A but have also highlighted its therapeutic potential in addressing two significant health challenges affecting millions worldwide.Preliminary research suggests that BP1001-A may play a pivotal role in mitigating insulin resistance, a condition that often complicates the trea...
June 17, 2024
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials IncreasePALM BEACH, Fla., June 17, 2024 - According to a report from Mordor Intelligence, the Acute Myeloid Leukemia (AML) market is projected to reach a size of USD 2.97 billion by 2029, growing at a CAGR of 10.15% during the forecast period (2024-2029). This market is estimated to be worth USD 1.83 billion in 2024. The report highlights several key factors contributing to this growth, including the high incidence and prevalence of AML, advances in pharmacology and molecular biology, and increased investments in research and development by pharmaceutical companies.AML is a type of cancer characterized by the rapid ...
June 14, 2024
Bio-Path Holdings recently presented encouraging data from an ongoing phase 2 combination study of Prexigebersen at the European Hematology Association (EHA) Congress. The presentation highlighted positive outcomes from an interim analysis, revealing significant clinical improvement and a tolerable safety profile when using Prexigebersen in combination with other therapies for the treatment of acute myeloid leukemia (AML) in high-risk patients.Positive Data from Interim Analysis:The presented data underscored the potential of Prexigebersen in improving treatment outcomes for high-risk AML patients. The interim analysis demonstrated significant clinical improvements in patients who received Prexigebersen in c...
May 24, 2024
Bio-Path Holdings Reports Promising Developments in Acute Myeloid Leukemia Therapies at Upcoming EHA Congress: Prexigebersen Interim Success and BP1002 Milestone Bio-Path Holdings Reports Promising Developments in Acute Myeloid Leukemia Therapies at Upcoming EHA Congress: Prexigebersen Interim Success and BP1002 MilestoneBio-Path Holdings, a biotechnology company dedicated to advancing novel cancer treatments, will present pivotal findings at the forthcoming 2024 European Hematology Association (EHA) Congress, spotlighting significant strides in the therapeutic landscape for Acute Myeloid Leukemia (AML). The culmination of these efforts underscores the company s commitment to addressing unmet medical needs i...
April 18, 2024
In the quest for more effective treatments for refractory/relapsed Acute Myeloid Leukemia (AML), Bio-Path Holdings has successfully completed the higher dose second cohort in a groundbreaking Phase 1/1b clinical trial of its innovative drug, BP1002. This announcement brings new hope to AML patients who are resistant to the commonly used medication, venetoclax.AML is a devastating form of leukemia that affects the bone marrow and blood. Current treatments often involve the use of venetoclax, a targeted therapy that inhibits the B-cell lymphoma 2 (Bcl-2) protein, thereby triggering apoptosis (programmed cell death) in cancer cells. However, some AML patients develop resistance to venetoclax, making their treat...
Bio-Path Holdings, a promising cancer therapeutics company, has successfully completed the first dose cohort for its ongoing Phase 1/1b clinical trial of BP1002. This innovative drug, devised to treat refractory/relapsed Acute Myeloid Leukemia (AML), is demonstrating the broad and untapped potential for RNA interference (RNAi) therapies in combating drug-resistant malignancies. AML, a rapid, fatal form of cancer impacting blood and bone marrow, remains a formidable challenge in the oncology space. Despite advances in treatment, the malignancy s high resistance rate to conventional drugs presents a recurring roadblock for practitioners and researchers alike. Much hope, therefore, rests on therapeuti...
Opko Health Inc is a biotechnology and pharmaceutical company that operates through various business segments. The company primarily focuses on diagnostics, developing and commercializing novel diagnostic tests for various conditions. Additionally, Opko Health engages in the production and sale of pharmaceuticals and vaccines, as well as the research and development of new medical technologies.
Kezar Life Sciences Inc is a biotechnology company that focuses on developing novel small molecule therapeutics. Their business model revolves around the discovery and development of innovative drugs to target autoimmune and inflammatory disorders, aiming to address unmet medical needs. They primarily operate by conducting extensive research and conducting clinical trials to deliver effective treatments for patients.
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
Sources:
Bio path Holdings inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Bio path Holdings inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
